Bibliography
Found 41 results
Filters: Keyword is Anti-HIV Agents [Clear All Filters]
White matter damage, neuroinflammation, and neuronal integrity in HAND. J Neurovirol. 2019 ;25(1):32-41.
Better executive function is independently associated with full HIV suppression during combination therapy. AIDS. 2019 ;33(15):2309-2316.
. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis. 2017 ;215(1):105-113.
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.
Osteopontin is increased in HIV-associated dementia. The Journal of Infectious Diseases [Internet]. 2008 ;198:715-22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18616394
. Exosome markers associated with immune activation and oxidative stress in HIV patients on antiretroviral therapy. Sci Rep. 2018 ;8(1):7227.
. Measures of Physical and Mental Independence Among HIV-Positive Individuals: Impact of Substance Use Disorder. AIDS Res Hum Retroviruses. 2017 ;33(10):1048-1055.
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology. 2015 ;84(3):241-50.
Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother. 2010 ;54(12):5156-60.
Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. Antimicrob Agents Chemother. 2017 ;61(1).
. Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs. Antimicrob Agents Chemother. 2019 ;64(1).
HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nature Reviews. Neuroscience [Internet]. 2007 ;8:33-44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17180161
. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.
Efficacy and safety of two-drug regimens for treatment of HIV in the central nervous system. AIDS. 2020 ;34(13):1975-1977.
. Can research at the end of life be a useful tool to advance HIV cure?. AIDS. 2017 ;31(1):1-4.
. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol. 2016 ;22(4):479-87.
Psychometric validation of the BDI-II among HIV-positive CHARTER study participants. Psychol Assess. 2015 ;27(2):457-66.
. Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. J Infect Dis. 2016 ;213(7):1065-73.
Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. Neurology. 2019 ;92(12):e1344-e1353.
Macrophages but not Astrocytes Harbor HIV DNA in the Brains of HIV-1-Infected Aviremic Individuals on Suppressive Antiretroviral Therapy. J Neuroimmune Pharmacol. 2019 ;14(1):110-119.
. Emerging Patterns in HIV-1 gp120 Variable Domains in Anatomical Tissues in the Absence of a Plasma Viral Load. AIDS Res Hum Retroviruses. 2019 ;35(6):588-596.
. Brain-specific HIV Nef identified in multiple patients with neurological disease. J Neurovirol. 2018 ;24(1):1-15.
. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. Journal of Neurovirology [Internet]. 2006 ;12:100-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16798671
.